Get the Stockscreener App
27.02
0.66%
-0.18
After Hours:
27.00
-0.02
-0.07%
Alkermes Plc stock is traded at $27.02, with a volume of 1.70M.
It is down -0.66% in the last 24 hours and down -21.38% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.20
Open:
$27.05
24h Volume:
1.70M
Relative Volume:
0.99
Market Cap:
$4.54B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
13.86
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+1.62%
1M Performance:
-21.38%
6M Performance:
-4.62%
1Y Performance:
+12.54%
1-Day Range:
$26.98
$27.52
1-Week Range:
$26.30
$28.02
52-Week Range:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
27.02 | 4.54B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
148.66 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus
Alkermes' CFO Iain Brown passes away (ALKS:NASDAQ) - Seeking Alpha
Alkermes CFO Iain M. Brown passes away By Investing.com - Investing.com India
AlkermesCFO Iain M. Brown Passes AwaySEC Filing - MarketScreener
Alkermes (ALKS) announces passing of Chief Financial Officer - StreetInsider
Alkermes plc Announces Demise of Iain M. Brown, Chief Financial Officer - MarketScreener
Massachusetts biotech company cuts 90% of its workforce - NBC Boston
Mural Oncology cuts 90% of staff, pulls plug on cancer drug - The Business Journals
5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io
Alkermes to Participate in Two Upcoming Investor Conferences - Seeking Alpha
Alkermes To Present At Needham Virtual Healthcare Conference; Webcast At 11:45 AM ET - Nasdaq
Opioid Use Disorder Market Generated Opportunities, Future - openPR.com
Alcohol Addiction Treatments Market Detailed in New Research - openPR.com
Opioid Withdrawal Treatment Market Emerging Trends and Growth - openPR.com
Relative Strength Alert For Alkermes - Nasdaq
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 - MSN
RBC Trims Price Target on Alkermes to $39 From $40, Keeps Sector Perform Rating - MarketScreener
Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Malaysian Reserve
Alkermes Begins Idiopathic Hypersomnia Study On ALKS 2680 - Barchart.com
Nanotechnology Drug Delivery Market Exclusive Trends Analysis - openPR.com
Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia - Sharecast News
Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia - MarketScreener
(ALKS) Trading Report - news.stocktradersdaily.com
Deutsche Bank Adjusts Alkermes Public Price Target to $52 From $40, Maintains Buy Rating - MarketScreener
What 5 Analyst Ratings Have To Say About Alkermes - Benzinga
New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder - PR Newswire
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition? - MSN
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Liposomal Drug Delivery Market Detailed In New Research Report - openPR.com
First Week of November 21st Options Trading For Alkermes (ALKS) - Nasdaq
Controlled Release Drug Delivery Market to Witness Massive - openPR.com
Alkermes price target raised to $35 from $34 at BofA - MSN
Where are the Opportunities in (ALKS) - news.stocktradersdaily.com
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Why Is Alkermes (ALKS) Down 6.6% Since Last Earnings Report? - Yahoo Finance
Is Alkermes plc (ALKS) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Alkermes PLC Reports Q4 Revenue of $430 Million, Beating Estimat - GuruFocus.com
Alkermes' (NASDAQ:ALKS) investors will be pleased with their splendid 140% return over the last five years - Yahoo Finance
Alkermes (NASDAQ:ALKS) shareholders have earned a 19% CAGR over the last five years - Simply Wall St
Alkermes Facing Near-Term Headwinds Across Existing Franchises, Royalties, RBC Says - Marketscreener.com
RBC Capital Initiates Coverage of Alkermes (ALKS) with Sector Perform Recommendation - Nasdaq
S&P 500 Futures Drop in Premarket Trading; Alkermes, Intel Lead - Barron's
Alkermes initiated with a Sector Perform at RBC Capital - TipRanks
Charles Schwab Investment Management Inc. Sells 38,088 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights - Investing.com India
Alkermes at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com South Africa
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 25 '25 |
Sale |
35.26 |
3,743 |
131,978 |
7,717 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 20 '25 |
Sale |
35.69 |
1,327 |
47,361 |
7,717 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
30.12 |
144,419 |
4,350,097 |
202,294 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Option Exercise |
19.64 |
199,196 |
3,912,871 |
262,796 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Sale |
32.78 |
204,921 |
6,718,278 |
57,875 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Sale |
35.53 |
144,419 |
5,130,698 |
57,875 |
1.93%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):